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Abstract
Background: Anemia is a common complication of  chronic kidney disease. We investigated the prevalence, characteristics 
and management of  anemia in patients on chronic hemodialysis and assessed the response to blood-transfusion based man-
agement in Cameroon.
Methods:  This  was  a  cohort  study  of   five  months’  duration  (August-December  2008) conducted at the Yaoundé 
General Hospital’s hemodialysis center, involving 95 patients (67 men, 70.5%) on chronic hemodialysis by a native arter-
io-venous fistula. A monthly evaluation included  full blood  counts,  number  of  pints  of  red cell concentrates  transfused, 
and vital status.
Results: At baseline, 75 (79%) patients had anemia which was microcytic and hypochromic in 32 (43%). Anemia was cor-
rected in 67 (70.5%) patients using blood transfusion only, while 28 (29.5%) patients were receiving erythropoietin  (11 regu-
larly, 39%). Only 77.2% of  342 pints (median 3.0, range 0-17 per patients) of  red cell concentrates prescribed were effectively 
received during the follow-up at an unacceptably high cost to patients and families.   Mean hemoglobin and mean corpuscu-
lar hemoglobin levels remained stable during follow-up, while mean corpuscular  volume increased.  Erythropoietin  treat-
ment was the main determinant of  favorable trajectories of  hematological markers.
Conclusions: Patients on chronic hemodialysis have predominantly microcytic hypochromic anemia, with limited capacity 
for correction using blood transfusion.
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Anemia is a common complication of  chronic kidney 
disease (CKD) which is associated with increased mor-
bidity and mortality . The prevalence of  anemia corre-
lates with the severity of  kidney impairment, and ranges 
from about 1% in stage 2 of  CKD to almost 100% in 
end stage renal disease (ESRD) or chronic hemodialysis 
(CHD) patients2-5. Although diminishing erythropoietin 
production by the failing kidney is a major contributor, 
the etiology of  anemia in CKD is multifactorial involv-
ing among other factors, deficiency in iron, B12 vita-
mins and folate,  shortened  red  blood  cell  lifespan, 
blood  loss,  “uremic  environment”, hyperparathy-
roidism,   inflammation,   aluminum   toxicity   and   hy-
pothyroidism6.   With   the discovery of  erythropoiesis 
stimulating agents (ESA) some 30 years ago, the preven-
tion and management of  renal anemia have significantly 
improved in developed countries. However, the prohib-
itive cost of  these therapies and the lack of  a third payer 
system in resource-poor settings implies most patients 
in developing countries cannot afford them2,3. In addi-
tion, anemia in such settings like sub-saharan African 
(SSA) countries is likely more frequent in patients with 
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CKD as a result of  context specific factors like nutri-
tional deficiencies, hemoglobinopathies,  infectious and 
parasitic diseases7,8. In this context, management of  
anemia heavily relies on blood transfusion, a paradox 
given the scarcity of  safe blood in these settings with 
various endemic infectious diseases2,3. In general how-
ever, little is known about the prevalence of  anemia in 
patients  on chronic  hemodialysis  in SSA  and its evo-
lution  under  blood  transfusion-based management.
In Cameroon, a SSA country, the care of  ESRD pa-
tients requiring dialysis has improved over the recent 
years following government subsidized access to hemo-
dialysis9. This governmental support  however,  does 
not  cover  the care  of  comorbidities  including  ane-
mia.  Hence,  the management  of   anemia  in  patients 
on  dialysis  in  this  setting  is  mainly  based  on  blood 
transfusion, despite the absence of  a coordinated na-
tional blood transfusion service. Thus, it seemed ap-
propriate to examine the prevalence, characteristics and 
management of  anemia in patients on chronic hemo-




This was a prospective cohort study of  five months du-
ration from 1st August to 31st December 2008  con-
ducted  at the Yaoundé  General  Hospital  (YGH)  he-
modialysis  center.  The study center has been described 
in detail previously10. In brief, this center is one of  the 
two government-funded dialysis centers that serve the 
needs of  the entire country (population: 19 millions) 
at the time this study was conducted. The center is 
equipped with 12 hemodialysis generators that use the 
Fresenius® 4008S dialysis technology (Fresenius Med-
ical Care, Homburg, Germany), synthetic polysulfone 
dialysis membrane, and bicarbonate. The center oper-
ated  from  Monday  to  Saturday  and  offered  to 
registered  patients  two  hemodialysis sessions  of   4 
hours  duration  each  per  week.  This  study  was  ap-
proved  by the  Cameroon National Ethics Committee, 
and participants or their next-of-kin provided written 
informed consent.
Data collection
During the study period, all consenting patients who 
had been on chronic dialysis for at least 3 months with 
the use of  a native arterio-venous fistula were includ-
ed in the study. Patients who presented with an acute 
illness were excluded. Baseline demographic, clinical 
and laboratory data were collected at inclusion during 
the first week of  participant’s recruitment, including 
age, sex, dry weight, duration on dialysis and full blood 
count (FBC).  Furthermore, the etiological factors  of  
CKD  and comorbidities  were  noted.  Full  blood 
counts  were  repeated  monthly throughout  the  study 
period  using  blood  collected  from  the  arterial  dialy-
sis  line  at  the beginning of  the first dialysis session of  
the month. The full blood count exam was done free of  
charge to the participants  for the purpose of  the study. 
The hemoglobin  (Hb) level, the mean  corpuscular 
volume  (MCV)  and  mean  corpuscular  hemoglobin 
(MCH)  levels  were noted for analysis. According to the 
Kidney Disease Outcome Quality Initiative (K-DOQI) 
guidelines, anemia was defined by hemoglobin levels 
less than 11 g/dl11. For the purpose of  the study, ane-
mia requiring blood transfusion was defined by hemo-
globin levels less than 9.0 g/dl. Microcytosis and mac-
rocytosis were defined respectively by MCV < 80 and > 
100 fl. Hypochromia and normochromia were defined 
by MCH < 27 and ≥ 27 pg respectively. Dry weight 
was the theoretical weight of  the patient necessary to 
perform well-tolerated dialysis sessions without cramps 
and hypotension. Patients receiving at least 50 IU per 
kilogram per week of  erythropoietin  were considered 
to be “regularly on erythropoietin”,  as opposed to “oc-
casional intake” attributed to all who were on  doses of  
less than 50 IU per kilograms per week.
The French Health Products Safety Agency (AFSSAPS) 
recommendations  were applied to estimate the number 
of  pints of  red cell concentrates (RCC), to determine the 
rate of  blood transfusion and to monitor blood trans-
fusion12. The formula applied was Np = (WBV/100) 
(tHb – iHb)/QHbpc;  where Np is the number of  pints 
of  RCC; WBV (ml) is whole blood volume; tHb (g/dl) 
is the target hemoglobin (11.0 g/dl); iHb (g/dl) is the 
initial hemoglobin level; QHbpc (g) is the quantity of  
hemoglobin in each unit of  RCC (it was estimated at 
45 g per unit). The WBV was determined using the “5 
rules of  GILCHER”12: for a female subject:
Normal= 70 ml/kg, Underweight= 65 ml/kg, Obese= 
60 ml/kg. WBV values for male subjects are those for 
female augmented with 5 ml/kg. Blood was obtained 
from the blood bank of  the YGH. Transfusion was ex-
ecuted during dialysis session at a rate of  8 ml/min with 
the vital parameters monitored according to the AFS-
SAPS recommendations.
Statistical analysis 
Statistical analysis used SPSS® version 17.0 for Win-
dows. Means and standard deviations, medians, ranges 
and percentages were used to express results. Person χ2 
test and equivalents, and Student t-test and non-para-
metric equivalents were used to compare qualitative and 
quantitative variables. Mixed linear regression models 
were used to examine changes in hematological param-
eters during follow-up and relate baseline or follow-up 
levels of  potential predictors of  those changes. Effects 
of  baseline variables on all-cause mortality during fol-
low- up were investigated through logistic regression 
models. A “p” value of  < 0.05 was used to indicate sta-
tistically significant results.
Results
Baseline profile of  patients
At the beginning of  the study, 109 patients were on 
chronic hemodialysis in the centre among which 7 
(6.4%) were dialyzed for less than 3 months, 4 (3.6%) 
were dialyzed by a catheter and 3 (2.7%) refused to par-
ticipate in the study. A total of  95 patients (67 men, 
70.5%) were recruited, including 93 (97.9%) with hy-
pertension,  28 (29.5%) with diabetes and 6 (6.3%) with 
HIV infection,  comparably  among  men and women 
(all p≥0.27),  and irrespective  of  status for erythropoi-
etin use (all p ≥0.22), Table 1. 
The overall age of  patients ranged from 18 to 75 years 
with a mean of  47.6±14.3 years. As presented in Table 
1, patients had been on dialysis for a median duration 
of  6.5 months (range 4-64), with no significant  differ-
ences observed either by sex or use of  erythropoietin 
(both p≥0.10). The dry weight of  the patients ranged 
 
Table 1 - Baseline profile of participants overall and by gender 
 
 





























Characteristic Overall Men Women p-value No EPO On EPO p-value 
N 95 67 28  67 28  
Males sex, n 67 67 0  49 18 0.46 
Mean age, years (SD) 47.6 (14.3) 48.5 (12.7) 45.2 (17.7) 0.38 47.9 (14.6) 46.8 (13.7) 0.74 
Median duration in dialysis, months (min-max) 6.5 (4-64) 8 (4-64) 4 (4-54) 0.32 5.0 (4-11) 8.8 (4.5-22.7) 0.10 
Mean weight, kg (SD) 61 (11.1) 62.9 (11.1) 56.8 (9.8) 0.008 59 (9) 66 (13) 0.007 
Hypertension, n 93 65 28 >0.99 65 28 >0.99 
Diabetes, n 28 17 11 0.27 17 11 0.22 
HIV infection, n 6 5 1 0.67 4 2 >0.99 
Tuberculosis, n 5 3 2 0.63 3 2 0.63 
Mean hemoglobin level, g/dl (SD) 8.6 (1.9) 8.7 (1.7) 8.3 (2.4) 0.35 8.3 (1.9) 9.2 (1.7) 0.05 
Hemoglobin level <11 g/dl, n 75 55 20 0.24 55 20 0.28 
Mean corpuscular volume, fl (SD) 78.7 (7.7) 77.8 (7.7) 80.8 (7.4) 0.07 78.4 (8.5) 79.3 (5.4) 0.62 
Microcytosis, n 56 40 16 0.82 39 17 >0.99 
Mean corpuscular hemoglobin, pg (SD) 26.8 (2.5) 26.7 (2.5) 27.2 (2.3) 0.40 26.8 (2.7) 27.0 (2.0) 0.68 
Hypochromia, n 37 26 11 0.96 34 15 0.83 
Iron treatment, n 17 12 5 >0.99 2 15 <0.0001 
Erythropoietin treatment, n    0.69    
None 67 49 18     
Occasionally 17 11 6     
Regularly 11 7 4     
from 40 to 98 kg with a mean of  61.0±11.1 kg overall; 
it was 62.9±11.1 kg (range 45-98) in men and 56.8±9.8 
kg (range 40-72) in women with a significant difference 
(p=0.008). In the erythropoietin-treated group, the 
mean dry weight was 66±13 kg (range 49-98), signifi-
cantly  higher  than  59±9  kg  (range  40-69)  in  those 
not  receiving  erythropoietin (p=0.007).
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Mean age, years (SD) 47.6 (14.3) 48.5 (12.7) 45.2 (17.7) 0.38 47.9 (14.6) 46.8 (13.7) 0.74 
Median duration in dialysis, months (min-max) 6.5 (4-64) 8 (4-64) 4 (4-54) 0.32 5.0 (4-11) 8.8 (4.5-22.7) 0.10 
Mean weight, kg (SD) 61 (11.1) 62.9 (11.1) 56.8 (9.8) 0.008 59 (9) 66 (13) 0.007 
Hypertension, n 93 65 28 >0.99 65 28 >0.99 
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Mean hemoglobin level, g/dl (SD) 8.6 (1.9) 8.7 (1.7) 8.3 (2.4) 0.35 8.3 (1.9) 9.2 (1.7) 0.05 
Hemoglobin level <11 g/dl, n 75 55 20 0.24 55 0 .28 
Mean corpuscular volume, fl (SD) 78.7 (7.7) 77.8 (7.7) 80.8 (7.4) 0.07 78.4 (8.5) 79.3 (5.4) 0.62 
Microcytosis, n 56 40 16 0.82 39 17 >0.99 
Mean corpuscular hemoglobin, pg (SD) 26.8 (2.5) 26.7 (2.5) 27.2 (2.3) 0.40 26.8 (2.7) 27.0 (2.0) 0.68 
Hypochromia, n 37 26 11 0.96 34 15 0. 3 
Iron treatment, n 17 12 5 >0.99 2 15 <0.0001 
Erythropoietin treatment, n       0.69       
None 67 49 18         
Occasionally 17 11 6         
Regularly 11 7 4         
EPO – Erythropoietin; HIV – Human Immunodeficiency Virus; SD – Standard Deviation.
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Hematological profile and prevalence of  anemia 
Baseline hematological parameters are described in Ta-
ble 1. Mean values were 8.6 g/dl (range 3.3-14.0) for 
hemoglobin level, 78.7 fl (range 55-99) for mean glob-
ular volume and 26.8 pg (range  18-32)  for  mean  cor-
puscular  hemoglobin,  with  no  significant  difference 
observed either by sex or use of  erythropoietin (both 
p>0.05). At baseline, 75 (79%) participants had
anemia with characteristic presented in Figure 1.
Figure  1 – Baseline  characteristics  of  the anemia  overall,  and by sex and status  for erythropoietin 
(EPO treatment
Anemia correction at baseline and during follow-up
At baseline, 28/95 (29.5%) patients were initially on 
erythropoietin among which 11 (11.6%) on  regular 
erythropoietin  with  7  (7.4%)  men  and  15  (15.8%) 
receiving  IV  iron  therapy. Therefore  67 patients 
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Men                Women              Overall             No EPO            On EPO
For  each  subgroup,  the  proportional  contribution 
of   each  type  of   anemia  to  the  total population with 
anemia (100%) within that subgroup is indicated by a 
specific pattern on the vertical bar, each time with the 
accompanying percentage. The p-values comparing the 
distribution of  type of  anemia between men and wom-
en, and between participants on EPO vs. those not on 
EPO are also shown, always displayed between the ver-
tical bars representing the subgroups been compared. 
Horizontal bars have been added at 20% intervals to 
assist visual interpretation.
iron at baseline, Table 1.
During follow-up, 22 (23%) patients were excluded for 
various reasons including death or transfer to another 
dialysis center (see the next section for more details) 
without any clinically significant difference of  their pro-
file compared to the remaining patients (Online Table 
1). During  the  study  period,  a total  of  342 pints  of  
RCC  (median  4.0 pints,  range  0-18  per patients) 
were prescribed to the 73 patients with valid follow-up, 
but they effectively received only 264 (77.2%)  pints of  
RCC (median 3.0 pints, range 0-17 per patients).  The 
out- of- pocket payment for blood transfusion   by   pa-
tients, excluding staff  charges, ranged from ≈ US$ 0 to 
627.2 (median US$ 141.6), based on a conversion rate 
of  US$ 1=XAF 500. The monthly variation in the num-
ber of  blood units received and related cost is show in 
the Online Table 2.
Trajectories of  hematological parameters during 
follow-up
Hemoglobin levels increased between baseline and first 
month, and remained stable during the 2 subsequent 
months, before dropping at the final month (Figure 
2). After a drop between baseline and month 1, MCV 
levels steadily increased during follow-up. The trend 
was also towards increasing levels of  MCH during fol-
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Figure 2 – Trajectories of  hematological parameters during follow-up
For each figure panel, the solid curve depicts the trajec-
tory of  the relevant parameters during follow-up, and 
the dotted line about are for the 95% confidence inter-
val. The mean values of  each parameter at baseline and 
during follow-up are also displayed. The superimposed 
dotted horizontal lines on each figure panel are to assist 
the visual interpretation. 
In mixed linear regression analysis, being on erythro-
poietin was associated with 1.1 g/dl (range 0.6-1.6) 
higher levels of  hemoglobin, 2.6 fl (range 0.4-4.9) high
er MCV level and 0.9 pg (range 0.1-1.6) higher levels of  
MCH (Table 2). 
An inverse association was observed between blood 
transfusion and hemoglobin  level (likely reflecting  the 
reverse causality),  whereby  each unit of  RCC was as-
sociated with 0.7 g/dl (range 0.6-0.9) lower hemoglobin 
levels. In addition, each 10-month duration on dialysis 
was associated with 0.3 g/dl (range 0.2-0.4) higher he-
moglobin levels, and iron therapy with 0.5 g/dl (range 
0.1-0.9) higher hemoglobin, while non-diabetic had 2.4 
fl (range 0.6-4.2) higher MCV than diabetics (Table 2).
Month of  follow-up 
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Table 2 - Determinants of changes in hematologic parameters during follow-up, based 
on mixed linear regression models 
 
 
EPO – Erythropoietin ; HIV – Human Immunodeficiency Virus. 






Intercept 9.4 (8.4 to 10.5) 83.6 (78.7 to 88.6) 26.9 (25.2 to 28.5) 
 
Men vs. women 
 
Age (per 10 years) 
 
0.1 (-0.2 to 0.5) 
 
0.07 (-0.04 to 0.2) 
 
-1.3 (-2.9 to 0.3) 
 
0.9 (0.4 to 1.5) 
 
-0.2 (-0.7 to 0.4) 
 
0.3 (0.2 to 0.5) 
 
Duration in dialysis (per 10 months) 
No diabetes vs. diabetes 
No HIV vs. HIV infection 
 
No iron vs. iron therapy 
 
0.3 (0.2 to 0.4) 
 
-0.01 (-0.4 to 0.4) 
 
0.04 (-0.6 to 0.7) 
 
-0.5 (-0.9 to -0.1) 
 
-0.4 (-0.9 to 0.1) 
 
2.4 (0.6 to 4.2) 
 
-0.3 (-3.3 to 2.8) 
 
-1.7 (-3.5 to 0.2) 
 
-0.2 (-2.5 to 1.4) 
 
0.8 (0.2 to 1.5) 
 
-0.1 (-1.6 to 0.9) 
 
-0.4 (-1.1 to 0.2) 
 
No EPO vs. EPO therapy 
 
Blood transfusion (per pint) 
 
-1.1 (-1.6 to -0.6) 
 
-0.7 (-0.9 to -0.6) 
 
-2.6 (-4.9 to -0.4) 
 
-0.1 (-0.7 to 0.5) 
 
-0.9 (-1.6 to -0.1) 
 
-0.1 (-0.2 to 0.1) Fatal outcomes
According to the vital status of  the 95 participants, 18 
(19%) patients (12 men, 63.1%) died and 4 (4%) moved 
to a different dialysis center, with no difference ob-
served either in sex (p=0.60),  or by status for eryth-
ropoietin  treatment (p=0.29 for erythropoietin  treat-
ment vs. none and p=0.36 for regular erythropoietin 
treatment vs. irregular or none). In age and sex adjusted 
logistic regression analysis, baseline dry weight [odd ra-
tio per kg higher level: 0.88 (95% confidence interval 
0.81-0.96)] was significantly associated with lower mor-
tality risk. Hematological parameters including anemia 
and its characteristics were not associated with mortal-
ity.
Discussion
In this study based on a convenient sample of  patients 
on chronic hemodialysis, receiving care in one of  the 
main hemodialysis  centers in Cameroon, 79% had ane-
mia which was mainly microcytic  hypochromic,  and 
blood transfusion  was  the  dominant  strategy  for 
correcting anemia. Only about 77% of  the estimated 
blood requirements were effectively received during 
the observation period, at a very high cost in the study 
context. As a result, improvements in the  trajectories 
of   hematological  parameters  during  follow-up  was 
modest,  and  mostly observed among those who were 
receiving erythropoietin or IV iron, non-diabetics  or 
had been  on  dialysis  for  a  longer  duration.  Death 
rate  was  very  high  during  follow-up,  but unrelated 
to baseline hematological profile.
The higher prevalence  of  anemia in our study was 
within the range of  figures reported in similar groups 
of  patients elsewhere2,3,13-15. However, the predomi-
nantly microcytic and hypochromic  patterns could be 
explained  either by the inflammatory  state associated 
with chronic  infection  or by the presence  of  context 
specific  factors (not investigated)  such as nutritional 
deficiencies, hemoglobinopathies  and parasitic diseas-
es7,8. In our setting, chronic hemodialyzed  patients were 
younger,  likely including more individuals  in their pro-
ductive years,  mainly  unemployed  and  facing  finan-
cial  constraints  for  their  care  as  previously reported 
in  similar  settings.   This  could  affect  their  capacity 
for  coping  with  ESRD management, including caring 
for complications such as anemia1,10,16.
Just about three quarters of  the estimated blood amount 
required by patients was effectively received during fol-
low-up. This result constitutes one of  the relevant in-
formation provided by this study which was difficult 
to obtain before the study period regarding the delay 
between blood prescription and effective transfusion 
to patient. This non-optimal achievement of  the esti-
mated blood transfusion likely explained the dropping 
hemoglobin level after two months of  follow-up.  This 
non-optimal  rate  of  RCC  received  by patients  could 
be  related  to the scarcity of  safe blood in this setting 
where various infectious diseases including HIV/AIDS,
viral   hepatitis   and   syphilis,   and   hemoglobinopthies 
are   highly   endemic17.   
Moreover, inadequate hemodialysis related to the prac-
tice of  only 2 weekly hemodialysis sessions could be 
an additional factor. The difficulties of  patients to re-
ceive the amount of  RCC required could also be due to 
the unacceptably higher cost of  transfusion to patients 
and their families in the absence of  social security pro-
grams. With the absence of  national blood transfusion 
centre  in Cameroon,  the blood  bank  in the study 
hospital  and many  others  operate  on a compensation 
mode whereby, a patient in need of  blood provides two 
donors for each pint of  RCC. More so, he must pay for 
the different screening tests carried out on the blood 
(about US $40 per pint), and cover the blood donors 
fees. This does not include staff  charges. These issues 
and the complexity of  financing mechanisms for blood 
transfusion in resources-limited settings  have  been 
nicely clarified  in a study by Hensher  & Jefferys17. 
 However,  chronic hemodialyzed  patients  have  chronic 
anemia  due  to  the  lack  of   erythropoietin  production 
related to ESRD, achieving effective anemia correction 
in these patients in such settings by blood  transfusion 
can  be  very  challenging  due  to  the  scarcity  of   safe 
blood  as  already mentioned and the absence of  a coor-
dinated national blood transfusion service. In order to 
reduce the risk of  blood transmitted diseases in our set-
ting, improved access to ESA and IV iron  should   be 
the  best  way  for  correcting   ESRD   related   anemia 
as  recommended elsewhere11,13-15.  As  of   now,  eryth-
ropoietin  and  IV  iron  accessibility  is  limited  by  the 
prohibitive cost which was about US$ 30 for 2000 IU 
of  erythropoietin and US$ 25 for 100 mg of  IV iron at 
the time this study was conducted.  Moreover,  in spite 
of  government’s subsidies, patients on chronic hemo-
dialysis must pay the equivalent of  US$ 12 per dialysis 
session [US$ 1248 per annum,  which is higher than the 
gross national  income (GNI) per capita of  US$ 1210 in 
201118 excluding fees of  others comorbidities.
Our study has some limitations. These include the rel-
atively small and non-random sample, the recruitment 
of  participants from a single center and the short du-
ration of  follow-up. Comorbidities were mainly based 
on prevalent (diagnosed comorbidity) which may un-
derestimate  the true prevalence  of  those conditions 
in our sample  and accordingly  bias estimates of  their 
association with anemia in CKD. We were also unable 
to investigate the full spectrum of  etiology of  anemia 
in our population related to the high cost of  exams and 
the absence of  study funding. For instance, we could 
have learned more by investigating the iron status, B12 
vitamin and folate, reticulocyte counts, G6PD status, 
hemoglobin electrophoresis status, inflammatory mark-
ers and stool test for occult blood or parasites. 
There are however some  concerns  about  the  yield  of  
such  investigations.  An  investigation  of   iron  status  in 
Tunisian chronic hemodialyzed patients revealed a 22% 
iron deficiency, with only 2% of  the patients presenting 
with microcytic hypochromic anemia14. Our study also 
has some strengths in the sense that it provides a unique 
picture, which, in this setting can potentially contribute
to raise more attention on anemia, a leading condition 
in people with CKD. It revealed the positive correla-
tion between hematological profile and erythropoietin 
and IV iron therapy in a few patients receiving these 
therapies, even in non-optimal dose, due to financial 
constraints as reported in similar setting14,15. Our efforts 
in tracking a large number of  our participants during 
follow-up provides some indicators of  the burden of  
anemia in chronic hemodialysis patients and the out-
come of  anemia correction approaches in the context 
of  limited access to ESA  and  intravenous   iron  thera-
pies.   This  study  provides   also  some  answers   to  the 
government queries and the counseling of  patients to 
be admitted in chronic hemodialysis.
Conclusion
There is a high prevalence of  anemia in CKD patients 
and failure or limited capacity for correction via blood 
transfusion-based treatment in this setting where blood 
transfusion could be unsafe, where the pool of  blood 
donor is very restricted, and where the cost of  transfu-
sion or alternative correction approaches such as ESA 
or IV iron use remain very prohibitive.  Strategies to 
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Intercept 9.4 (8.4 to 10.5) 83.6 (78.7 to 88.6) 26.9 (25.2 to 28.5) 
 
Men vs. women 
 
Age (per 10 years) 
 
0.1 (-0.2 to 0.5) 
 
0.07 (-0.04 to 0.2) 
 
-1.3 (-2.9 to 0.3) 
 
0.9 (0.4 to 1.5) 
 
-0.2 (-0.7 to 0.4) 
 
0.3 (0.2 to 0.5) 
 
Duration in dialysis (per 10 months) 
No diabetes vs. diabetes 
No HIV vs. HIV infection 
 
No iron vs. iron ther py 
 
0.3 (0.2 to 0.4) 
 
-0.01 (-0.4 to 0.4) 
 
0.04 (-0.6 to 0.7) 
 
-0.5 (-0.9 to -0.1) 
 
-0.4 (-0.9 to 0.1) 
 
2.4 (0.6 to 4.2) 
 
-0.3 (-3.3 to 2.8) 
 
-1.7 (-3.5 to 0.2) 
 
-0.2 (-2.5 to 1.4) 
 
0.8 (0.2 to 1.5) 
 
-0.1 (-1.6 to 0.9) 
 
-0.4 (-1.1 to 0.2) 
 
No EPO vs. EPO therapy 
 
Blood transfusion (per pint) 
 
-1.1 (-1.6 to -0.6) 
 
-0.7 (-0.9 to -0.6) 
 
-2.6 (-4.9 to -0.4) 
 
-0.1 (-0.7 to 0.5) 
 
-0.9 (-1.6 to -0.1) 
 
-0.1 (-0.2 to 0.1) 
 EPO – Erythropoietin ; HIV – Human Immunodeficiency Virus.
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improve anemia management in CKD patients could 
include and are not limited to: 1) the establishment of  
coordinated national blood transfusion service; 2)  the 
implementation   of   cost-recovery   policies  by  blood 
transfusion   service;  3)  the subsidized access of  ESA 
and IV iron therapy and 4) the CKD prevention pro-
gram to reduce the growing population of  people in 
need of  renal replacement therapy. 
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